Climb Bio (CLYM)

• Market cap: $129M
• 1 day: 2.72%
• 5 days: 9.88%
• 1 month: -9.13%
• 3 months: -17.83%
• 6 months: 51.2%
• Year to date: -8.7%
• 1 year: -41.49%
• 5 years: -88.11%
• 10 years: -88.11%
• Sector: Healthcare
• Industry: Biotechnology

About: Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.

Employees: 18